&Partners’s SELLAS Life Sciences SLS Stock Holding History

&Partners’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$158K	Sell	10,690 -251	-2%	-$1.73K	﹤0.01%	2421
2026 Q1	$46.3K	Buy	+10,941	New	+$48.9K	﹤0.01%	2367

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

&Partners's SLS Position: Q2 2026 in Review

&Partners reduced its SELLAS Life Sciences (SLS) stake by 2.3% in Q2 2026, selling an estimated $1.73K and leaving 10,690 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #2421.

&Partners first reported a position in SLS in Q1 2026 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

&Partners held 10,690 shares of SELLAS Life Sciences worth $158K as of Q2 2026.
&Partners sold 251 SELLAS Life Sciences shares in Q2 2026, an estimated $1.73K.
SELLAS Life Sciences made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2421 holding.
&Partners first reported a position in SELLAS Life Sciences in Q1 2026 and has held it in 2 quarters since.
192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.